Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6528974 | 0.88 | MAPT (0.55) | CYP1A2CYP2C9CYP2C19PLA2G1BCYP3A4 | |
| SCHEMBL6530153 | 0.84 | CYP1A2 (0.42) | CYP1A2CYP2C9CYP2C19PLA2G1BCYP3A4 | |
| SCHEMBL6529029 | 0.80 | MAPT (0.41) | CYP1A2CYP2C9CYP2C19PLA2G1BCYP3A4 | |
| SCHEMBL6527944 | 0.80 | MAPT (0.43) | CYP1A2CYP2C9CYP2C19PLA2G1BCYP3A4 | |
| SCHEMBL6491702 | 0.79 | GAA (0.49) | CYP1A2CYP2C9CYP2C19PLA2G1BCYP3A4 | |
| SCHEMBL6775812 | 0.77 | MAPT (0.43) | MEN1KMT2AMAPTALDH1A1PTGIR | |
| SCHEMBL6770092 | 0.77 | MAPT (0.43) | CYP1A2CYP2C9CYP2C19PLA2G1BCYP3A4 | |
| SCHEMBL6768996 | 0.77 | RAB9A (0.45) | CYP1A2CYP2C9CYP2C19PLA2G1BCYP3A4 | |
| SCHEMBL6527513 | 0.76 | UTS2R (0.45) | CYP3A4MAPTPTGIRIDO1DHODH | |
| SCHEMBL6493321 | 0.76 | CYP2C19 (0.45) | CYP1A2CYP2C9CYP2C19PLA2G1BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | claimed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | claimed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | claimed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | claimed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | claimed |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | WARNER LAMBERT COMPANY | 2005-04-07 | — | — | US | disclosed |
| US-6800656-B2 | Tricyclic compounds and method of treating herpes virus | WARNER LAMBERT COMPANY | 2004-10-05 | — | — | US | disclosed |
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | BOOTH RICHARD JOHN (US) | 2003-12-11 | — | — | US | disclosed |
| EP-1248777-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2002-10-16 | — | — | EP | disclosed |
| WO-2001051479-A2 | TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY | WARNER-LAMBERT COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229073-A1 | Tricyclic compounds and method of treating herpes virus | HDAC8, ZC3HAV1, ZCCHC8 | CYP1A2 649/4885CYP2C9 1728/4885CYP2C19 2948/4885 |
| US-20050075332-A1 | Tricyclic compounds with antiviral activity | HDAC8, CDK8, ZC3HAV1 | CYP1A2 2938/4885CYP2C9 2166/4885CYP2C19 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.